Please login to the form below

Not currently logged in
Email:
Password:

GW hires Pfizer’s Kenneth Sommerville

Appointed VP clinical research at company specialising in cannabinoids

Dr Kenneth Sommerville has left his role at pharma giant Pfizer to join GW Pharma.

Dr Sommerville was VP, clinical sciences, at Pfizer for three years having joined the company from King Pharmaceuticals.

At GW he will assume in the newly-created role of VP, clinical research, where he will lead clinical development, medical affairs, and regulatory activities related to the company's work in epilepsy, pain and other diseases.

GW's research is focused on the development of cannabinoids. This includes Sativex, which became the world's first plant-derived cannabinoid prescription drug when it was approved for multiple sclerosis in Canada and the European Union in 2010. It is also in clinical trials for other indications, including cancer pain.

"This is an exciting time to be joining GW, with a number of important products currently under development for patients in the US including Sativex and Epidiolex,” said Dr Sommerville.

8th May 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Windrose Consulting Group

Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...

Latest intelligence

The concordance conundrum: the art of active listening
The art of active listening explores the links between effective communication and better patient concordance and medical outcomes, why many HCPs still overestimate their ability to communicate effectively and the...
Article
Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma...
Infographic
Migraine market snapshot...

Infographics